U.S. markets closed

Acasti Pharma Inc. (ACST)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.1100+0.0800 (+3.94%)
At close: 4:00PM EDT
2.0500 -0.06 (-2.84%)
After hours: 07:16PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close2.0300
Open2.0400
Bid2.1000 x 1800
Ask2.1200 x 2200
Day's Range1.9900 - 2.1350
52 Week Range1.3600 - 9.7600
Volume558,948
Avg. Volume1,259,730
Market Cap94.094M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.9800
Earnings DateNov 15, 2021 - Nov 19, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.52
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Acasti Pharma, Inc.
    Analyst Report: Zoetis Inc.Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
    Rating
    Fair Value
    Economic Moat
    9 hours agoMorningstar
View more
  • GlobeNewswire

    Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

    LAVAL, Québec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021. Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma, is scheduled to present on Tuesday, September 21, 2021 at 2:05 PM Eastern Time. Management will also be participating in one-on-one meetings with qualified members of the i

  • GlobeNewswire

    Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    LAVAL, Québec, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announced that Jan D’Alvise, President and Chief Executive Officer of Acasti Pharma, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. Acasti’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 13, 2021, at 7:0

  • Motley Fool

    Why Shares of Acasti Pharma Slumped Tuesday

    Acasti Pharma (NASDAQ: ACST) fell by more than 18% in Tuesday trading. The company said that it had closed its merger with Grace Therapeutics; former Acasti shareholders now own 59% of the combined company. The second -- and more concerning -- part of the announcement was that the company would perform an 8-1 reverse split at the start of trading on Aug. 31.